New weapon against tough ovarian cancer enters human testing
NCT ID NCT06234423
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called CUSP06 for people with ovarian cancer that has stopped responding to platinum chemotherapy, as well as other advanced solid tumors. CUSP06 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly to cells that carry a specific marker (CDH6). The study will enroll about 263 participants to first find the safest dose and then check for early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CUSP06 (an antibody-drug conjugate that targets CDH6 on cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with ovarian cancer that no longer responds to platinum chemotherapy.
What could go wrong
This is a very early Phase 1 trial, so the main goals are safety and dosing—not yet proof of effectiveness. It may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Mater Cancer Care Centre
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
Contact
-
Mount Sinai Medical Center
RECRUITINGMiami Beach, Florida, 33140, United States
Contact
-
NEXT Oncology
RECRUITINGHouston, Texas, 77054, United States
Contact
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
NYU Cancer Institute Clinical Cancer Center
RECRUITINGNew York, New York, 10016, United States
Contact
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
Sarah Cannon Research Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
Contact
-
Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact
-
Yale University
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact